Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes

Guardiola, Montse; Rehues, Pere; Amigó, Núria; Arrieta, Francisco; Botana, Manuel; Gimeno-Orna, José A.; Girona, Josefa; Martínez-Montoro, José Ignacio; Ortega, Emilio; Pérez Pérez, Antonio; Sánchez-Margalet, Víctor; Pedro-Botet, Juan Carlos; Ribalta, Josep; Cardiovascular Disease Group of the Spanish Society of Diabetes

doi:http://dx.doi.org/10.1111/eci.14214

Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes

License

Citation

Guardiola M, Rehues P, Amigó N, Arrieta F, Botana M, Gimeno-Orna JA, et al. Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes. Eur J Clin Invest. 2024 Aug;54(8):e14214. DOI: 10.1111/eci.14214

Abstract

The burden of cardiovascular disease is particularly high among individuals with diabetes, even when LDL cholesterol is normal or within the therapeutic target. Despite this, cholesterol accumulates in their arteries, in part, due to persistent atherogenic dyslipidaemia characterized by elevated triglycerides, remnant cholesterol, smaller LDL particles and reduced HDL cholesterol. The causal link between dyslipidaemia and atherosclerosis in T2DM is complex, and our contention is that a deeper understanding of lipoprotein composition and functionality, the vehicle that delivers cholesterol to the artery, will provide insight for improving our understanding of the hidden cardiovascular risk of diabetes. This narrative review covers three levels of complexity in lipoprotein characterization: 1-the information provided by routine clinical biochemistry, 2-advanced nuclear magnetic resonance (NMR)-based lipoprotein profiling and 3-the identification of minor components or physical properties of lipoproteins that can help explain arterial accumulation in individuals with normal LDLc levels, which is typically the case in individuals with T2DM. This document highlights the importance of incorporating these three layers of lipoprotein-related information into population-based studies on ASCVD in T2DM. Such an attempt should inevitably run in parallel with biotechnological solutions that allow large-scale determination of these sets of methodologically diverse parameters.